EC Status and Availability


EC ever use among women of reproductive age: 0.9% (DHS 2005)

EC knowledge among women of reproductive age: 26.8% (DHS 2010)

Contraceptive Use: 26.1% (DHS 2005, ever use of any modern method among women of reproductive age)

Registered LNG-EC products:

  • Escapelle* - Available directly from pharmacist without prescription (i.e. BTC)
  • Postinor* - Available directly from pharmacist without prescription (i.e. BTC)

Registered UPA-EC products:

  • Dvella* - Available only with prescription

Registered Mifepristone-EC Products:

Products marked with * have been approved by a stringent regulatory authority, such as the WHO Prequalification Programme, the US Food and Drug Administration, the European Medicines Agency, or other.

Where at least one type of ECP is available: Private clinics, Pharmacies, IPPF-affiliated system

Age restrictions for accessing ECPs: No data available

Legal/regulatory documents in which EC is included: Essential Medicines List

Other relevant information: A product containing ulipristal acetate has been registered but is not yet on the market.

EC distributed via IPPF outlets (<500 in 2012).

In Armenia, the lowest cadre of health workers allowed to sell/dispense ECPs in the private sector is doctors, as of 2013. (USAID/DELIVER, Contraceptive Security Indicators, 2013)

In 2013, EC was not procured by the government (JSI/Deliver data).

Our country-by-country information comes from numerous sources, including partners from around the world. We have made every effort to ensure that the information included here is correct, but EC availability and policies can change quickly. We welcome your additions and/or corrections

To submit updates and corrections to ICEC, click here.

Begin a new search